Photo Courtesy: Allogene Therapeutics Metastatic renal cell carcinoma (RCC) is an advanced form of kidney cancer with few treatment options and a five-year survival rate of less than 17%. With funding support from CIRM, Allogene Therapeutics is developing ALLO-316, an allogeneic CAR-T cell therapy which targets CD70—a protein highly expressed on clear cell renal cell … Continue reading A Step Forward in the Fight Against Advanced Kidney Cancer
Cancer
Two CIRM-funded research projects receive RMAT designation from FDA
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to two research projects funded by the California Institute for Regenerative Medicine (CIRM). RMAT is a fast-track designation that can help speed up the development, review, and potential approval of treatments for serious or life-threatening diseases. The first RMAT designation … Continue reading Two CIRM-funded research projects receive RMAT designation from FDA
From Undergraduate to Hero: Solano Student’s Life-Saving Bone Marrow Match Begins with One Swab
SCC student and CIRM trainee Jose Solorio donated bone marrow to save an 11-year-old patient's life in New York. In a remarkable display of compassion and scientific collaboration, Solano Community College (SCC) student Jose Solorio, a scholar in the college's biomanufacturing bachelor's program, has become a real-life hero. Through Solano’s partnership with the National Marrow … Continue reading From Undergraduate to Hero: Solano Student’s Life-Saving Bone Marrow Match Begins with One Swab
CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
The California Institute for Regenerative Medicine (CIRM) is proud to announce the allocation of $26 million to support clinical research targeting a range of cancers, heart conditions, and rare diseases. This significant funding underscores CIRM’s commitment to advancing innovative stem cell and gene therapy-based treatments through all stages of clinical trial development. This latest round … Continue reading CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
Gene therapy trial tests cancer-killing virus in brain tumors
Dr. Noriyuki Kasahara from UCSF has been awarded $11.8 million by the California Institute for Regenerative Medicine (CIRM) to target newly diagnosed high-grade gliomas. This groundbreaking clinical trial aims to treat high-grade gliomas, one of the most challenging brain cancers to manage. These aggressive cancers develop in the brain or spinal cord and are notoriously … Continue reading Gene therapy trial tests cancer-killing virus in brain tumors
Supporting a CAR-T cell trial for kidney cancer
Photo Credit: Allogene Therapeutics. Image of the ALLO-316 allogeneic CAR-T cell therapy. The California Institute for Regenerative Medicine (CIRM) awarded $15 million to Dr. John Le Gall and his team at Allogene Therapeutics. This funding will support the development of ALLO-316, an innovative anti-CD70 CAR-T cell product designed to treat metastatic clear cell renal cell … Continue reading Supporting a CAR-T cell trial for kidney cancer
CIRM’s $31 million boost for cancer and eye disease research
The California Institute for Regenerative Medicine (CIRM) recently approved nearly $31 million in funding, further cementing our commitment to advancing the field of regenerative medicine. This substantial investment aims to drive clinical research targeting various cancers and eye diseases. CIRM’s dedication to fostering innovative treatments is demonstrated through its clinical program, which funds eligible stem … Continue reading CIRM’s $31 million boost for cancer and eye disease research
Identifying a Potential New Stem Cell Treatment for Ovarian Cancer
Stock image of a uterus and ovaries model. The California Institute for Regenerative Medicine (CIRM) has awarded a $5.3 million to Karen Aboody, MD of City of Hope for late-stage preclinical research to develop a neural stem cell mediated treatment for a chemo-resistant, metastatic ovarian cancer. Approximately 22,000 women are diagnosed with ovarian cancer—the most … Continue reading Identifying a Potential New Stem Cell Treatment for Ovarian Cancer
CIRM Joins #GoGold Childhood Cancer Awareness Campaign
Photo courtesy of Stanford Medicine September is Childhood Cancer Awareness Month and the California Institute for Regenerative Medicine (CIRM) is joining the campaign to #GoGold to raise awareness about childhood cancers and highlight our commitment to funding childhood cancer research. The Impact of Childhood Cancer Cancer remains the number one cause of death by disease for … Continue reading CIRM Joins #GoGold Childhood Cancer Awareness Campaign
CIRM board member Ysabel Duron appointed to National Cancer Advisory Board by President Biden
Ysabel Duron is an award-winning journalist, patient advocate, cancer survivor and board member of the California Institute for Regenerative Medicine (CIRM). Her list of achievements continues to grow, as President Biden has appointed Duron to National Cancer Advisory Board (NCAB), which plays an important role in setting the course for the national cancer research program. … Continue reading CIRM board member Ysabel Duron appointed to National Cancer Advisory Board by President Biden
The Stem Cellar 